The European Commission has approved Roche’s Susvimo implant for neovascular age-related macular degeneration, offering continuous ranibizumab delivery with refills every six months and creating a fundamentally different alternative to repeated eye injections.
FDA approval gives adults with fibrodysplasia ossificans progressiva another treatment option after OPTIMA recorded just one to two new bone lesions with Pasatru versus 19 with placebo over 56 weeks.
FDA approves Regeneron’s Pasatru after Phase 3 data showed a 90% reduction in new FOP bone lesions. See what the new therapy means.
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.